Drugs / sirpiglenastat
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07430202 | Aug 2026 → Aug 2030 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06027086 | Feb 2024 → Sep 2028 expected | fibrolamellar hepatocellular carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04471415 | Aug 2020 → Mar 2023 | non-small cell lung carcinoma | Dracen Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07249372 | Jan 2026 → Oct 2027 expected | non-small cell lung carcinoma | NYU Langone Health | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sirpiglenastat | “In addition, we observed a profound decrease in tumor growth in several in vivo models using sirpiglenastat (DRP-104), a pro-drug version of DON that was designed to circumvent...” PMID 37814010 ↗ Oct 2023 |
| Known as | DRP-104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07249372 ↗ |
| Action | Inhibit | “DRP-104, a Glutamine Antagonist” NCT04471415 ↗ |
| Modality | Small molecule | — CHEMBL4650367 ↗ |
| Route | Intravenous | “DRP-104 administered intravenously over 1 hour” NCT04471415 ↗ |